Search the Newsreel

Stevanato Group (NYSE: STVN) targets 26.8% 2026 EBITDA margin

Stevanato Group reported strong Q2 2026 results with an 8% revenue increase and a 26% adjusted EBITDA margin, driven by growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and High Value Solutions. The company updated its full-year 2026 guidance, targeting a 26.8% adjusted …

Impressive Earnings May Not Tell The Whole Story For Carvana (NYSE:CVNA)

Carvana Co. 2026 Q2 - Results - Earnings Call Presentation (NYSE:CVNA) 2026-08-06

Former penny stock nearing bankruptcy reports record profit

Carvana was once a stock that Wall Street wrote off. In December 2022, shares traded for less than $1 apiece (split-adjusted) after losing almost all their value in a single year. Bankruptcy talk was everywhere. Now the online used vehicle retailer is posting the …

Australian Vanadium Reinforces Resource Base and Integrated Value Strategy

Stevanato Group S.p.A. Stock 12‑Month Price Target Raised to $25.1, Implies 28% Upside

Stevanato Group S.p.A.'s average stock price target has been raised from $24.95 to $25.1 by 10 analysts, suggesting a potential 28% upside from the August 4th closing price. The consensus rating among 12 covering analysts remains a "Buy," with 10 Buys and 2 Holds. …

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. That's …

Stevanato Group Details Mid-2026 Performance and Risk Landscape in Unaudited Interim Report

Stevanato Group has filed an unaudited interim report for Q2 2026, outlining its financial performance and discussing key operational risks such as supply chain issues, geopolitical tensions, and post-pandemic demand normalization. The report emphasizes the importance of quality, innovation, and brand reputation for competitiveness. …

Carvana Co. (CVNA) VP sells 5,000 shares under Rule 10b5-1 plan

Carvana Co.'s Vice President of Accounting, Stephen R. Palmer, sold 5,000 shares of Class A Common Stock on August 3, 2026, across four transactions at volume-weighted average prices between $63.19 and $65.82 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading …

335,493 Shares in Stevanato Group S.p.A. $STVN Purchased by Confluence Investment Management LLC

Confluence Investment Management LLC has purchased a new stake of 335,493 shares in Stevanato Group S.p.A., valued at approximately $6.06 million, representing 0.11% of the company. Other institutional investors like Conestoga Capital Advisors, Van Berkom & Associates, Jennison Associates, and Roubaix Capital also increased …

Stevanato Group SpA (STVN) (Q2 2026) Earnings Call Highlights: Biologics Surge and Alina ...

Stevanato Group (STVN) reported an 8% revenue increase in Q2 2026, driven by a 9% rise in biopharmaceutical and diagnostic solutions and a 30% surge in biologics revenue. The company saw an adjusted EBITDA margin expansion to 26% and achieved a significant milestone with …

Carvana Co. (NYSE: CVNA) CEO reports 134,707-share award and tax withholding

Carvana Co.'s CEO, Ernest C. Garcia III, received an equity compensation award of 134,707 Class A Common Stock shares through restricted stock units. These units will vest 25% on April 1, 2027, with the remainder vesting monthly over the subsequent three years, contingent on …

Stevanato Group (STVN) Stock Faces Cash Strain Despite Margin Gains

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported an 8% revenue increase in Q2 2026, driven by a 9% rise in biopharmaceutical and diagnostic solutions and a 30% surge in biologics revenue. The company saw an adjusted EBITDA margin expansion to 26% and achieved a significant milestone with …

Stevanato Group SpA Revenue Breakdown – MUN:87N

Stevanato Group SpA (MUN:87N) reported a total revenue of €1.19 billion last year. The majority of this revenue, €997.60 million, came from its Biopharmaceutical and Diagnostic Solutions segment. EMEA was the largest contributing region, generating €663.30 million.

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group reported an 8% increase in revenue for the second quarter of fiscal 2026, reaching €302.0 million, primarily driven by its Biopharmaceutical and Diagnostic Solutions Segment. The company also updated its full-year 2026 guidance, expecting revenue between €1.260 billion and €1.280 billion, and …

Craftech Holdco acquired Balda C. Brewer, Inc. from Stevanato Group S.p.A..

Craftech Holdco successfully acquired Balda C. Brewer, Inc. from Stevanato Group S.p.A. on June 30, 2026. This transaction involved Stevanato Group S.p.A., which is listed on the NYSE under the ticker STVN. The news was published on August 4, 2026, at 5:23 pm EDT.

Carvana Co. (CVNA) CFO exercises options, sells 63,750 shares

Carvana Co.'s CFO, Mark W. Jenkins, exercised non-qualified stock options for 63,750 shares and subsequently sold all of them on August 3, 2026, for approximately $4.11 million. These transactions were carried out under a Rule 10b5-1 trading plan adopted in 2024. Additionally, Jenkins acquired …

Carvana (CVNA) grants 119,883 RSUs, withholds shares to pay taxes

Carvana's chief product officer, Daniel J. Gill, was granted 119,883 restricted stock units (RSUs) that will vest 25% on April 1, 2027, with the remainder vesting monthly over the next three years, contingent on his continued employment. Additionally, 7,707 shares were withheld at $62.36 …

Carvana (NYSE: CVNA) grants 56,742 RSUs; 2,881 shares withheld for taxes

Carvana's Chief Brand Officer, Ryan S. Keeton, was

Carvana Co. (CVNA) grants 85,336 RSUs; 4,453 shares withheld for taxes

Carvana Co.'s Vice President, General Counsel, Secretary, and Chief Compliance Officer, Paul W. Breaux, was granted 85,336 shares of Class A Common Stock underlying restricted stock units. These RSUs will vest 25% on April 1, 2027, with the remainder vesting monthly over the following …

Stevanato Group (NYSE: STVN) grows H1 revenue, records disposal loss

Stevanato Group (NYSE: STVN) grows Q2 sales 8% and updates 2026 view

Stevanato Group (NYSE: STVN) announced an 8% increase in Q2 2026 sales, primarily driven by a 9% rise in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and strong demand for High-Value Solutions (HVS), which grew 16%. The company also updated its full-year 2026 guidance, …

Stevanato Group (NYSE: STVN) grows Q2 revenue and sells Balda subsidiary

Carvana Just Posted Record Numbers And Got Crushed. Here's The Math

Carvana Just Posted Record Numbers And Got Crushed. Here's The Math Carvana had the best quarter in its history on Wednesday and got its head kicked in for it. Nearly 200,000 cars retailed, revenue up more than half, record operating income, record SG&A efficiency …

Stevanato Group (NYSE:STVN) Releases Earnings Results, Beats Expectations By $0.01 EPS

Stevanato Group (NYSE:STVN) Updates FY 2026 Earnings Guidance

Sage Park Acquires Balda C. Brewer, the California-based Contract Manufacturing Injection Molding Subsidiary From Stevanato Group S.p.A.

ANAHEIM, CA / ACCESS Newswire / August 4, 2026 / Craftech Holdco, a portfolio company of Sage Park, today announced the acquisition of Balda C. Brewer ("BCB"), the Ontario, California-based contract manufacturing subsidiary, from its parent company, Stevanato Group S.p.A ("Stevanato"). BCB is a …

Stevanato Group Q2 2026 Earnings Call: Complete Transcript

Stevanato Group reported an 8% year-over-year revenue growth in Q2 2026, reaching $302 million, driven by strong demand for injectable biologics and GLP-1 therapies. The company divested its California subsidiary, Balda C. Brewer, to focus on higher-value integrated drug delivery systems, a move expected …

Stevanato Group (STVN) Q2 Earnings Top Estimates

Stevanato Group (STVN) reported Q2 earnings of $0.16 per share, surpassing the Zacks Consensus Estimate of $0.15, and revenues of $351.09 million, which slightly missed the consensus. The company has consistently beaten EPS estimates over the past four quarters and currently holds a Zacks …

Stevanato Group SpA earnings beat by €0.01, revenue topped estimates

Stevanato Group SpA (NYSE: STVN) reported strong second-quarter results, with EPS of €0.14 surpassing analyst estimates by €0.01 and revenue reaching €302M, exceeding the consensus estimate of €298.64M. The company's stock has seen a 14.20% increase in the last three months, despite a 10.83% …

Weekly Recap: Record Q2 sales and Citigroup cuts target to $90

Carvana Co. Class A (NYSE:CVNA) reported record Q2 2026 sales, revenue, GAAP profit, and diluted EPS of about $0.42, along with 197,325 retail units sold. Despite expanding same-day seller pickup in Fort Myers, Citigroup cut its price target for CVNA to $90 from $93. …

Investors brace for Stevanato earnings amid GLP-1 packaging surge By Investing.com

Stevanato Group SpA is set to report its second-quarter earnings, with analysts expecting significant year-over-year growth in EPS and revenue. Investors are keenly watching the company's ability to leverage the booming GLP-1 obesity drug market and the broader biologics expansion, focusing on its shift …

Carvana's Record Quarter Wasn't Built on Used Car Prices — Here's What Actually Happened

Carvana's Record Quarter Wasn't Built on Used Car Prices — Here's What Actually Happened Carvana just printed the best quarter in its history, and the press release invites you to credit execution. Fine. But before anyone files this under "used car market goes brrr," …

(STVN) Volatility Zones as Tactical Triggers

This article analyzes Stevanato Group S.p.a. (NASDAQ: STVN) using AI models to provide tactical trading triggers. It highlights a potential shift in near-term sentiment and offers three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis …

Stevanato Group (STVN) Could Be 19% Undervalued As Alina Pen Approvals Expand In Europe

Stevanato Group (STVN) is experiencing mixed share price momentum despite recent marketing authorizations for its Alina 30 and Alina 50 pen injectors in Europe. The company is considered 18.6% undervalued with a fair value of $24.39, driven by increasing demand for its drug delivery …